More severe influenza season to be expected in Europe
Medium or high rates of influenza intensity are likely to be observed in the vast majority of EU and EEA countries, concludes ECDC annual risk assessment on influenza for the remainder of the season.
Medium or high rates of influenza intensity are likely to be observed in the vast majority of EU and EEA countries, concludes ECDC annual risk assessment on influenza for the remainder of the season. The number of severe cases of influenza as well as fatal outcomes especially among older people and other risk groups can be expected to rise.
Strenuous start of this influenza season
- Influenza activity in Europe started in week 50/2014 without a particular geographic progression, affecting the Netherlands, Sweden and England first, and then followed by Iceland, Malta and Portugal.
- Children between 0 and four years of age have been the most affected age group according to primary healthcare data in almost all reporting countries, similarly as in other seasons.
- Influenza-like illness and acute respiratory infections have been increasing in adults and older people in almost all countries.
- Most of the first affected countries report greater pressure on primary healthcare services during this season compared to the peak activity in previous season.
- Among the countries reporting hospitalised influenza cases, 34 fatal outcomes were reported, two thirds of these in the elderly.
Drifted A(H3N2) viruses dominant
- Subtype A(H3N2) viruses, known to cause more severe disease, are dominant in almost all reporting European countries.
- Majority of A(H3N2) viruses analysed are antigenically distinct from the A(H3N2) virus included in the vaccine for this season.
- Reduced vaccine effectiveness is expected as a result of this mismatch between the vaccine and the circulating influenza strains.
ECDC Director, Dr Marc Sprenger, said:“We face an influenza season that could be more severe and exert bigger pressure on health care systems than in the last few years. As each year, ECDC undertakes a risk assessment early in the season, combining a multitude of data sources and aiming to inform and strengthen EU and EEA countries in their response to the influenza epidemics.”
How to protect oneself and others from the flu
- Self-isolation when sick, hand-washing and good respiratory hygiene as well as cough etiquette remain simple yet effective measures to protect from catching or passing on influenza.
- A lower overall vaccine effectiveness due to the circulation of drifted A(H3N2) viruses is expected, however, the vaccine may still reduce complications and severe outcomes associated with this subtype of influenza viruses.
- Influenza vaccine offers good protection against the circulating A(H1N1)pdm09 viruses.
Antivirals particularly important this season
- Treatment and post-exposure prophylaxis with antivirals protects the elderly and people in other risk groups against severe influenza illness.
- The circulating viruses are susceptible to antiviral drugs oseltamivir and zanamivir.
Dr Marc Sprenger emphasizes:“In a season dominated by a drifted A(H3N2) strain of influenza viruses, more severe illness can be expected especially among older people and those in medical risk groups. It is therefore paramount that physicians across Europe consider treatment and post-exposure prophylaxis with antivirals especially for these patients.”
The annual ECDC risk assessment of seasonal influenza aims to provide an early description of seasonal influenza in the first affected countries and to inform public health decisions to be taken to reduce the burden of seasonal influenza in 2015 in Europe.
Read full risk assessment of seasonal influenza in the EU/EEA countries, 2014-2015
Influenza surveillance for the 2017-2018 season is starting
ECDC monitors and reports on influenza transmission and virus circulation in Europe on a weekly basis throughout the flu season, in collaboration with WHO Regional Office for Europe, in the report Flu News Europe.Read more
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.Read more
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more